Erythrina variegata (Fabaceae) Indian Coral Tree, Parijata, Tiger's Claw

Aug 12
24 min read

Erythrina variegata, known as the Indian Coral Tree or Parijata, is a deciduous, thorny tree whose leafless branches erupt in dense clusters of scarlet, claw-like flowers that briefly dominate the tropical landscape before giving way to a broad canopy of trifoliate leaves. The genus name, from the Greek erythros (red), announces the flower colour, though white and orange variants occur. The tree is planted across the Indian subcontinent, Southeast Asia, and the Pacific Islands as an ornamental, a shade tree for coffee and pepper plantations, and a living fence post. Its medicinal identity is less visible but equally vivid: bark, leaves, and seeds have been deployed for centuries in Ayurveda, Siddha, and Unani for conditions ranging from insomnia and anxiety to rheumatic pain and worm infestation. Modern pharmacological investigation, accelerating through 2025, has validated several of these traditional applications, identifying Erythrina alkaloids and isoflavonoids with significant neuromuscular blocking, anxiolytic, anti-inflammatory, and antimicrobial activities. The tree that briefly flames crimson across the spring sky is, for the rest of the year, a quiet pharmacopoeia.

1. Taxonomic Insights

Species: Erythrina variegata L.

Family: Fabaceae (Legume Family); Subfamily: Faboideae

Genus: Erythrina

Synonyms: Erythrina indica Lam., Erythrina corallodendron var. orientalis L., Erythrina variegata var. orientalis (L.) Merr.

The genus Erythrina comprises approximately 130 species of trees, shrubs, and herbaceous perennials distributed throughout the tropics and subtropics. The generic name derives from the Greek erythros, meaning "red," a reference to the flower colour of most species. The specific epithet variegata means "variegated," alluding to the sometimes mottled or multicoloured leaves of certain forms. The synonym Erythrina indica remains widely encountered in older Indian literature. The tree is often called Parijata in India, though this Sanskrit name is more properly applied to Nyctanthes arbor-tristis, creating a persistent nomenclatural ambiguity in classical Ayurvedic texts.

Botanical Description

Erythrina variegata is a medium-sized, deciduous tree, reaching 15 to 20 metres in height, with a spreading, open crown and a short, stout trunk. The architecture is distinctive: thick, ascending branches armed with sharp, conical prickles emerge from a bole that is often gnarled and buttressed in older specimens. The tree is leafless during flowering, a phenological strategy that renders the inflorescences maximally visible to pollinating birds.

Key Identification Features:

The bark is smooth and greenish-grey on young branches, becoming thick, deeply furrowed, and greyish-brown on mature trunks. The wood is soft, white, and spongy, making the tree fast-growing but susceptible to wind damage. Prickles are present on the trunk and branches: dark, conical, and sharply pointed, up to 1 centimetre long. The leaves are alternate, trifoliate, with long petioles (10 to 20 centimetres). Leaflets are rhomboid-ovate to broadly ovate, 8 to 20 centimetres long and 5 to 15 centimetres wide, with an acuminate apex and a broadly cuneate to truncate base. The terminal leaflet is larger than the lateral pair. Young leaves are bronze-coloured, maturing to a glossy bright green. The stipules are small and caducous. A pair of glandular stipels is present at the base of each leaflet.

The inflorescence is a dense, terminal raceme, 10 to 25 centimetres long, appearing on leafless branches. Flowers are large, showy, and papilionaceous, but with an inverted orientation: the standard petal is the largest and most conspicuous, scarlet to crimson (or white or orange in some cultivars), 5 to 8 centimetres long, and folded around the other petals. The keel and wing petals are much reduced. The calyx is spathaceous, splitting deeply on one side. There are 10 stamens, monadelphous (united into a single bundle). The ovary is stipitate, densely pubescent. The fruit is a woody, cylindrical pod, 15 to 30 centimetres long and 2 to 3 centimetres wide, deeply constricted between the seeds, brownish-black when mature. Seeds are 1 to 8 per pod, ellipsoid, 1.5 to 2 centimetres long, smooth, and reddish-brown to dark purple, with a prominent black hilum.

Distribution: The tree is native to the coastal forests of East Africa, the Indian subcontinent, Southeast Asia, southern China, Taiwan, the Ryukyu Islands, and through Malesia to northern Australia and the western Pacific Islands. It has been widely introduced and naturalised throughout the tropics, including the Caribbean, Central America, and West Africa. It grows from sea level to approximately 1500 metres elevation.

Conservation Status: The species has been assessed as Least Concern (LC) by the IUCN Red List. Its extensive natural range, wide cultivation, and naturalisation throughout the tropics render global extinction risk negligible.

Etymology

The generic name Erythrina is from the Greek erythros, "red." The specific epithet variegata is Latin for "variegated," possibly referring to the leaf colour in some forms. The common name "Coral Tree" describes the colour and shape of the flowers. "Tiger's Claw" refers to the sharp, curved prickles. The Indian name "Parijata" links the tree, incorrectly but tenaciously, to the celestial wish-fulfilling tree of Hindu mythology.

2. Common Names

3. Related Herbs from the Fabaceae Family

Erythrina variegata belongs to the Fabaceae, a family whose capacity for alkaloid biosynthesis has yielded some of the most important neuromuscular agents in medicine and toxicology.

Erythrina mulungu (Mulungu): A South American species used extensively in Brazilian traditional medicine as a sedative, anxiolytic, and anticonvulsant. Its Erythrina alkaloid profile, dominated by erythravine and related compounds, has been well characterised and its anxiolytic mechanism (nicotinic acetylcholine receptor antagonism) is partially elucidated. It serves as the most pharmacologically advanced reference species for the genus.

Erythrina abyssinica (Red Hot Poker Tree): An East African species used for infections, malaria, and inflammation. Its isoflavonoid content and antimicrobial activity provide a comparative framework for E. variegata.

Erythrina senegalensis: A West African species with traditional uses overlapping those of E. variegata, including antimicrobial and anti-inflammatory applications.

Mucuna pruriens (Velvet Bean): A fellow Fabaceous species rich in neurologically active compounds (L-DOPA). Its neuropharmacology provides a comparative reference for the CNS effects of Erythrina alkaloids.

Pueraria montana var. lobata (Kudzu): An isoflavonoid-rich legume used in Traditional Chinese Medicine. Its phytoestrogenic isoflavones (puerarin, daidzein) parallel the isoflavonoid constituents of Erythrina species.

The genus Erythrina is chemically defined by the co-occurrence of two major compound classes: Erythrina alkaloids (tetracyclic spiroamine alkaloids unique to the genus) and isoflavonoids (including prenylated isoflavones and pterocarpans). This dual chemotype underpins the genus's neuromuscular and anti-infective pharmacology.

4. Medicinal Uses: Summary of Primary and Secondary Actions

Primary Actions:

Neuromuscular Blocking and Anxiolytic: Erythrina alkaloids, particularly erythravine, erythrosine, and erysodine, act as competitive antagonists at nicotinic acetylcholine receptors. This action produces skeletal muscle relaxation, central nervous system depression, and anxiolysis. These effects form the pharmacological basis for the plant's traditional use as a sedative, sleep aid, and anticonvulsant.

Anti-inflammatory: Bark and leaf extracts demonstrate significant inhibition of carrageenan-induced paw edema, cotton pellet granuloma, and formalin-induced arthritis in rodent models. The mechanism involves inhibition of COX-2 and suppression of pro-inflammatory cytokines (TNF-α, IL-6) via NF-κB pathway modulation. Prenylated isoflavonoids are the primary active constituents.

Antimicrobial: Extracts show activity against a broad spectrum of bacteria, including Staphylococcus aureus, Bacillus subtilis, Escherichia coli, and Pseudomonas aeruginosa. Antifungal activity against Candida albicans, Aspergillus niger, and dermatophytes is also documented. The isoflavonoids, particularly phaseollin and erycristagallin, are the primary antimicrobial compounds.

Analgesic: Animal studies using acetic acid-induced writhing, hot plate, and tail-flick models have demonstrated significant, dose-dependent analgesic activity of bark and leaf extracts. The analgesic mechanism involves both peripheral (COX inhibition) and central (opioid receptor modulation) components.

Antioxidant: Methanolic and aqueous extracts of leaves and bark show significant free radical scavenging activity in DPPH, ABTS, and FRAP assays. The activity correlates with total phenolic and flavonoid content. Prenylated isoflavonoids are potent radical scavengers due to their phenolic hydroxyl groups.

Secondary Actions:

Anthelmintic: Bark and leaf extracts demonstrate dose-dependent paralytic and lethal activity against Pheretima posthuma (earthworm) and Ascaridia galli (poultry roundworm) in vitro, supporting traditional use for intestinal worms.

Anticonvulsant: The neuromuscular blocking activity of Erythrina alkaloids translates to anticonvulsant effects in animal models, including maximal electroshock and pentylenetetrazole-induced seizure models.

Hepatoprotective: Bark extracts have shown protective effects against carbon tetrachloride and paracetamol-induced hepatotoxicity in rats, with reductions in ALT, AST, and bilirubin levels.

Antiulcer: Leaf extracts have demonstrated gastroprotective activity in ethanol-induced and pylorus ligation-induced gastric ulcer models, with reductions in ulcer index and gastric acid secretion.

Antidiabetic: Preliminary studies report hypoglycemic activity of leaf extracts in alloxan-induced diabetic rats, with improvements in lipid profile parameters.

Hypotensive: Bark and leaf extracts produce a transient, dose-dependent reduction in blood pressure in anaesthetised animal models. This effect is consistent with the vasodilatory action of Erythrina alkaloids.

Anticancer: In vitro studies demonstrate cytotoxic activity of prenylated isoflavonoids and alkaloids against various human cancer cell lines, including breast (MCF-7), cervical (HeLa), and leukemia (K562) cells.

Medicinal Parts

Bark: The most frequently used medicinal part. A decoction is taken orally for insomnia, anxiety, fever, and rheumatic pain. Applied externally as a paste for joint inflammation and skin diseases. The bark is considered the richest source of Erythrina alkaloids.

Leaves: Used as a poultice for rheumatic joints, wounds, and boils. Leaf juice is applied to the eyes for conjunctivitis. A decoction is taken for cough, cold, and as a lactagogue to promote milk secretion in nursing mothers.

Seeds: Used internally, with caution, as an anthelmintic and for their neuromuscular effects. The seeds are toxic in large doses due to their alkaloid content and should only be used by experienced practitioners.

Roots: Used similarly to the bark, though less commonly. A paste is applied to rheumatic joints.

Flowers: The flowers are edible and used in certain Southeast Asian cuisines. They are considered a cooling food and are used in traditional preparations for fever.

5. Phytochemistry

The phytochemistry of Erythrina variegata is dominated by two structurally and pharmacologically distinct compound classes: Erythrina alkaloids and isoflavonoids.

5.1 Erythrina Alkaloids

Erythrina alkaloids are tetracyclic spiroamine alkaloids derived from the amino acid tyrosine. They are chemotaxonomically unique to the genus Erythrina and are responsible for its most characteristic pharmacological action: competitive antagonism at nicotinic acetylcholine receptors, producing curare-like neuromuscular blockade.

Erythravine: The major alkaloid in most Erythrina species, including E. variegata. It is a potent nicotinic acetylcholine receptor antagonist with demonstrated anxiolytic and anticonvulsant activity in animal models.

Erysodine: A major Erythrina alkaloid with neuromuscular blocking and antimicrobial activities.

Erysopine, erythraline, erythrinine, erythrosine: Structurally related alkaloids also present in the plant, contributing to the neuromuscular pharmacology. Their relative proportions vary depending on plant part, geographic origin, and season of collection.

Erythroidine (α-erythroidine and β-erythroidine): Present in some Erythrina species, particularly the Central and South American species. Their presence in E. variegata is less prominent but has been reported in some accessions.

5.2 Isoflavonoids

Isoflavonoids constitute the second major bioactive fraction and are responsible for much of the antimicrobial, anti-inflammatory, and antioxidant activity.

Prenylated isoflavones: Including alpinumisoflavone, wighteone, laburnetin, and eryvarin A through F. The prenyl (isopentenyl) side chain enhances lipophilicity and membrane penetration, potentiating antimicrobial activity. These compounds are characteristic of the genus.

Erycristagallin: A pterocarpan (a type of isoflavonoid) with potent antimicrobial activity, particularly against methicillin-resistant Staphylococcus aureus (MRSA). It is one of the most active antimicrobial compounds identified from the genus.

Phaseollin, phaseollidin, and sandwicensin: Antimicrobial pterocarpans identified in the bark and roots.

Genistein, daidzein, and their glycosides: Common isoflavones with phytoestrogenic, antioxidant, and anticancer activities. These are present in lower concentrations than the prenylated derivatives.

5.3 Other Phenolic Compounds

Flavonoids including quercetin, kaempferol, and their glycosides contribute to the antioxidant activity. Phenolic acids (caffeic acid, chlorogenic acid, ferulic acid) are present. Tannins are abundant in the bark, contributing to its astringency and antimicrobial activity.

5.4 Triterpenoids and Sterols

Oleanolic acid and ursolic acid are present and contribute anti-inflammatory and hepatoprotective activity. β-sitosterol and stigmasterol are the major phytosterols, with known anti-inflammatory and analgesic properties.

6. Mechanisms of Action

6.1 Neuromuscular Blocking and CNS Depressant Mechanism

Erythrina alkaloids are competitive antagonists at nicotinic acetylcholine receptors (nAChRs). They bind to the acetylcholine recognition site on the receptor without activating it, preventing endogenous acetylcholine from triggering the conformational change that opens the ion channel. At the neuromuscular junction, this results in flaccid paralysis of skeletal muscle, an effect that is qualitatively similar to that of curare (tubocurarine) but structurally distinct. In the central nervous system, antagonism at neuronal nAChRs (particularly the α4β2 and α7 subtypes) reduces excitatory neurotransmission, producing sedation, anxiolysis, and anticonvulsant effects. Erythravine has been shown to be particularly active at central nAChR subtypes, accounting for its pronounced anxiolytic activity in the elevated plus maze and light-dark box tests. This dual peripheral and central action, neuromuscular blockade combined with CNS depression, is the defining pharmacological signature of the genus.

6.2 Anti-inflammatory Mechanism

Prenylated isoflavonoids, particularly alpinumisoflavone and wighteone, inhibit the nuclear translocation of NF-κB, the master transcription factor governing the expression of COX-2, iNOS, and pro-inflammatory cytokines. The lipophilic prenyl group enhances cellular membrane penetration, increasing intracellular bioavailability. In LPS-stimulated RAW 264.7 macrophages, methanolic bark extract at 50 μg/mL reduced TNF-α production by over 50%. In animal models, the bark extract produced a dose-dependent reduction in paw edema volume comparable to indomethacin at the highest tested dose.

6.3 Antimicrobial Mechanism

The antimicrobial action of prenylated isoflavonoids and pterocarpans involves disruption of bacterial membrane integrity and inhibition of nucleic acid synthesis. Erycristagallin causes rapid depolarisation of the bacterial cytoplasmic membrane, leading to loss of membrane potential and leakage of intracellular contents. Against MRSA, erycristagallin has demonstrated MIC values as low as 1.56 μg/mL, comparable to standard antibiotics. The prenyl substituent is a critical structural determinant of this potency, increasing the compound's affinity for the hydrophobic interior of the bacterial membrane bilayer.

6.4 Analgesic Mechanism

The analgesic activity appears to involve both peripheral and central mechanisms. The efficacy in the acetic acid writhing test suggests a peripheral, cyclooxygenase-mediated component, consistent with the anti-inflammatory activity of the isoflavonoids. The efficacy in the hot plate and tail-flick tests, models of central nociception, suggests an additional, opioid-like or monoaminergic component. Erythrina alkaloids, by blocking neuronal nAChRs involved in pain processing in the spinal cord and brain, may contribute to this central analgesic effect.

6.5 Hepatoprotective Mechanism

The hepatoprotective effect against carbon tetrachloride is primarily antioxidant-mediated. The isoflavonoids and phenolic acids scavenge the trichloromethyl radicals generated during CCl4 metabolism by cytochrome P450, preventing the initiation of lipid peroxidation and the consequent destruction of hepatocyte membranes. The reduction in serum transaminases reflects preserved membrane integrity and reduced hepatocellular necrosis.

7. Traditional and Ethnobotanical Uses

7.1 Insomnia, Anxiety, and Nervous Disorders

Formulation: Bark decoction or powder.

Preparation and Use: A decoction prepared from the bark (5 to 10 grams dried bark in 400 millilitres water, boiled and reduced to 150 millilitres) is taken at bedtime for insomnia and restlessness. In Ayurveda, the bark is classified as a nidrajanana (sleep-promoting) and manasrogahara (mental disorder-alleviating) agent. A paste of the bark is sometimes applied to the forehead for headache and anxiety.

Scientific Validation: The anxiolytic and CNS depressant activities of Erythrina alkaloids, demonstrated in multiple animal models, provide a clear mechanistic basis. The antagonism at central nAChRs accounts for the sedative and anxiolytic effects. This is one of the most robustly validated traditional uses of the plant at the preclinical level. Human clinical data are absent.

7.2 Rheumatic and Arthritic Pain

Formulation: Bark paste, leaf poultice, or bark decoction.

Preparation and Use: The fresh bark is ground into a paste with a small amount of water and applied topically to painful, inflamed joints. A poultice of warmed leaves is similarly used. Internally, the bark decoction is taken for systemic relief. The tree is a common component of polyherbal formulations for vata disorders (musculoskeletal and neurological conditions) in Ayurveda.

Scientific Validation: The anti-inflammatory (NF-κB, COX-2 inhibition) and analgesic (peripheral and central) activities provide strong preclinical support. The isoflavonoids and Erythrina alkaloids contribute to the combined anti-inflammatory and analgesic effect.

7.3 Worm Infestations

Formulation: Bark decoction or seed paste.

Preparation and Use: A decoction of the bark is taken orally on an empty stomach to expel intestinal worms. The seeds, ground into a paste with water or jaggery, are also used, though this is considered a more potent and potentially toxic preparation. This anthelmintic use is recorded across India, Sri Lanka, and Southeast Asia.

Scientific Validation: The in vitro anthelmintic activity against Pheretima posthuma and Ascaridia galli provides preliminary evidence. The activity is attributed to the Erythrina alkaloids, which paralyse the worms' musculature through nicotinic receptor blockade. No human clinical trials have been conducted.

7.4 Skin Diseases and Wound Healing

Formulation: Bark or leaf paste.

Preparation and Use: A paste of the fresh bark or leaves is applied to boils, abscesses, eczema, and fungal skin infections. The bark paste is also applied to chronic, non-healing ulcers. A decoction is used as a wound wash.

Scientific Validation: The broad-spectrum antimicrobial activity, particularly the potency of erycristagallin against S. aureus (including MRSA), supports this traditional application. The anti-inflammatory activity aids in reducing the erythema and swelling associated with skin infections.

7.5 Fever and Inflammatory Conditions

Formulation: Bark decoction or leaf juice.

Preparation and Use: The bark decoction is used as an antipyretic and anti-inflammatory for febrile conditions. The leaf juice is taken with honey for cough and cold. In Southeast Asia, a decoction of the leaves is used as a gargle for sore throat.

Scientific Validation: The anti-inflammatory activity, and a probable antipyretic effect (though not specifically tested in animal models), support this traditional use.

7.6 Lactagogue Activity

Formulation: Leaf decoction or fresh leaf juice.

Preparation and Use: Nursing mothers in parts of India and Southeast Asia consume a decoction of the leaves to promote milk secretion. The leaves are considered galactogenic and are often included in postpartum dietary preparations.

Scientific Validation: The lactagogue claim has not been subjected to scientific investigation. Isoflavonoids with phytoestrogenic activity may, theoretically, influence prolactin secretion or mammary gland responsiveness, but this remains speculative.

7.7 Regional Ethnomedicinal Summary

Indian Subcontinent: The plant is used extensively in Ayurveda, Siddha, and Unani. Indications include insomnia, anxiety, rheumatic pain, worm infestation, skin diseases, and fever. The bark is the most commonly used part. The tree is often planted near temples and dwellings, its flowers used in worship.

Southeast Asia: In Thailand, Vietnam, and Indonesia, the bark and leaves are used for fever, cough, and as a diuretic and expectorant. The young leaves and flowers are consumed as a vegetable.

Pacific Islands: The bark is used in traditional medicine for inflammation and infections. In Samoa, the tree (Gatae) is used in ceremonial contexts and as a boundary marker.

East Africa: The bark is used for malaria, fever, and as an anti-inflammatory. The seeds are used, with caution, as a topical anaesthetic.

8. Healing Recipes, Teas, Decoctions, and Practical Applications

8.1 Bark Decoction for Insomnia and Anxiety

Purpose: To promote sleep and reduce mild anxiety. This is a traditional, mild sedative preparation. It is not a substitute for prescribed anxiolytic or hypnotic medication.

Preparation and Use: Take 5 grams of dried, coarsely powdered Erythrina variegata bark. Add to 300 millilitres of water in a stainless steel or earthen vessel. Bring to a boil, then reduce heat and simmer gently until the volume is reduced to approximately 100 millilitres. Strain through a clean muslin cloth. Allow to cool to a comfortably warm temperature. Consume 30 to 60 minutes before bedtime. This preparation is intended for occasional use, not as a daily hypnotic. Do not exceed the recommended dose. The sedative effect is attributable to Erythrina alkaloids acting on central nicotinic receptors.

Scientific Validation: The anxiolytic and CNS depressant activity of Erythrina alkaloids, particularly erythravine, is documented in animal models. Human clinical trials are absent. The onset and duration of the sedative effect in humans are not characterised.

8.2 Bark Paste for Rheumatic Joint Pain

Purpose: To reduce pain, swelling, and stiffness in arthritic and rheumatic joints.

Preparation and Use: Collect a piece of fresh Erythrina variegata bark, approximately 10 to 15 grams. Wash thoroughly. Using a clean mortar and pestle, grind the bark into a smooth, thick paste, adding a small amount of warm water as needed. Apply the paste in a thick layer over the affected joint. Cover with a clean cotton cloth and secure with a bandage. Leave in place for 2 to 3 hours. Repeat twice daily. The paste may produce a mild, transient warming sensation due to increased local blood flow.

Scientific Validation: The anti-inflammatory activity of the isoflavonoids (NF-κB and COX-2 inhibition) and the analgesic activity demonstrated in animal models support this traditional application. The topical absorption of active constituents has not been specifically studied.

8.3 Leaf Poultice for Boils and Wounds

Purpose: To treat localised skin infections, boils, and minor wounds.

Preparation and Use: Gather 10 to 15 fresh, mature leaves of E. variegata. Wash thoroughly. Warm the leaves briefly by placing them in a dry pan over low heat for 60 seconds. Crush the warmed leaves into a coarse paste. Apply the paste directly to the cleansed wound or boil. Cover with a sterile gauze pad and secure with a bandage. Change the dressing and reapply twice daily.

Scientific Validation: The antimicrobial activity of prenylated isoflavonoids and pterocarpans, particularly the potency against S. aureus, supports this use. The anti-inflammatory activity aids in reducing local inflammation. The wound should be thoroughly cleaned before application.

8.4 Culinary Uses of Leaves and Flowers

The young, tender leaves of E. variegata are consumed as a cooked vegetable in parts of India, Thailand, and Indonesia. They are typically boiled or steamed to reduce bitterness and then seasoned with spices and grated coconut. The flowers are also edible and are used in salads, stir-fries, and as a garnish. In Thai cuisine, the scarlet flowers are a striking addition to Yam Dok Thong Lang, a spicy salad. Nutritionally, the leaves and flowers are sources of protein, fibre, vitamins, and minerals, consistent with the edible leaf chemotype common in the Fabaceae. Only leaves and flowers from unsprayed trees should be consumed.

9. Clinical Significance and Evidence Summary

9.1 Evidence Hierarchy by Activity

Anxiolytic and CNS Depressant: Moderate to strong preclinical evidence. The nicotinic receptor antagonism by Erythrina alkaloids is well-characterised at the molecular level. Anxiolytic activity has been demonstrated in multiple rodent behavioural models. The genus Erythrina, particularly E. mulungu, has a substantial preclinical dossier supporting its sedative and anxiolytic effects. Human clinical trials are completely absent. This is the highest-priority clinical gap.

Anti-inflammatory: Moderate evidence from in vitro and animal studies. The NF-κB pathway inhibition and COX-2 suppression are documented. In vivo anti-inflammatory activity is comparable to standard NSAIDs at higher doses. Human data are absent.

Antimicrobial: Moderate to strong in vitro evidence. The activity of erycristagallin against MRSA (MIC 1.56 μg/mL) is particularly noteworthy. The prenylated isoflavonoid fraction represents a promising source of novel anti-infective scaffolds. In vivo infection models and clinical studies are lacking.

Analgesic: Moderate evidence from animal behavioural models. Peripheral and central mechanisms are implicated. Human data are absent.

Neuromuscular Blocking: Strong preclinical evidence. The curare-like activity of Erythrina alkaloids at the neuromuscular junction is a classical pharmacological observation, documented for over a century. This action forms the basis for the plant's traditional use as a muscle relaxant but also accounts for its potential toxicity.

Anthelmintic: Preliminary in vitro evidence. The data are limited to earthworm and poultry roundworm models. The mechanism (nicotinic receptor-mediated paralysis) is plausible. Human data are absent.

Hepatoprotective: Moderate evidence from animal models of chemically-induced liver injury. The antioxidant mechanism is plausible.

Anticonvulsant, Hypotensive, Antidiabetic, Anticancer: Preliminary evidence from in vitro and limited animal studies. These activities require independent replication and mechanistic elaboration.

9.2 Human Clinical Data

No human clinical trials have been published evaluating any therapeutic application of Erythrina variegata extracts or isolated compounds. This stands in contrast to the extensive preclinical data, particularly for the anxiolytic and neuromuscular blocking activities. The related South American species E. mulungu has been the subject of limited human studies for anxiety, with herbal preparations showing anxiolytic effects comparable to standardised Passiflora incarnata extract. These data provide a clinical precedent for the genus and underscore the translational potential of E. variegata.

9.3 Safety and Toxicology Data

The toxicity of Erythrina variegata is primarily attributable to Erythrina alkaloids and their curare-like neuromuscular blocking activity. The seeds are the most toxic plant part; ingestion can cause muscle weakness, respiratory depression, and, in severe cases, respiratory paralysis. All parts of the plant contain alkaloids, though in lower concentrations in the bark and leaves than in the seeds. Aqueous and hydroalcoholic bark extracts have shown low acute oral toxicity in rodent models at traditional doses, but the therapeutic index is narrower than that of many other medicinal plants. Overdose, particularly of seed-based preparations, carries a risk of significant neuromuscular depression.

10. Safety and Toxicology

10.1 Toxicity Profile

Acute Toxicity: Seeds are toxic. Ingestion of 5 to 10 seeds by an adult can produce symptoms of neuromuscular blockade, including muscle weakness, ptosis, diplopia, dysphagia, and, in severe cases, respiratory depression requiring ventilatory support. Fatalities are rare but have been reported in the literature. Bark and leaf extracts have lower acute toxicity; oral LD50 values in rodents generally exceed 2000 mg/kg for aqueous extracts.

Neuromuscular Toxicity: The principal toxicodynamic effect is competitive neuromuscular blockade, identical in mechanism to the therapeutic muscle relaxant effect but exaggerated at higher doses. The diaphragm, as the most critical skeletal muscle, is the ultimate target of toxicity.

Sub-acute and Chronic Toxicity: No systematic sub-chronic or chronic toxicity studies have been published. The potential for cumulative toxicity or organ-specific effects with prolonged use is unknown.

Reproductive Toxicity: No data. The phytoestrogenic isoflavonoids (genistein, daidzein) could theoretically influence reproductive function with prolonged, high-dose exposure. This remains uninvestigated.

10.2 Contraindications and Precautions

Pregnancy and Lactation: Oral use is contraindicated. The neuromuscular blocking activity and the complete absence of reproductive safety data prohibit any internal use during pregnancy. The safety of topical use has not been established. Lactation: The traditional use as a lactagogue does not imply safety; the alkaloid content of the leaves and their potential transfer into breast milk are unstudied.

Myasthenia Gravis and Neuromuscular Disorders: The nicotinic receptor antagonism of Erythrina alkaloids can exacerbate muscle weakness in myasthenia gravis and other disorders of neuromuscular transmission. Use is contraindicated.

Respiratory Insufficiency: The potential for respiratory muscle depression, even at therapeutic doses, makes internal use hazardous in individuals with compromised respiratory function, including severe COPD, sleep apnoea, and obesity hypoventilation syndrome.

Surgery: The neuromuscular blocking activity may potentiate the action of anaesthetic neuromuscular blocking agents (e.g., succinylcholine, rocuronium). Discontinue all internal use at least 2 weeks prior to elective surgery.

Children: Safety is unevaluated. Oral use is not recommended, particularly given the potential for neuromuscular toxicity.

10.3 Potential Drug Interactions

Anaesthetics and Neuromuscular Blocking Agents: Additive neuromuscular blockade. The clinical significance is potentially severe. Discontinue Erythrina preparations well in advance of surgery and inform the anaesthetist of any prior use.

Sedatives, Anxiolytics, and CNS Depressants (Benzodiazepines, Barbiturates, Alcohol, Opioids): Additive CNS depression and respiratory depression. The combination of Erythrina alkaloids with other sedatives can produce excessive sedation, respiratory depression, and increased risk of aspiration.

Antihypertensive Medications: The hypotensive activity of the extract, mediated by vasodilation, may potentiate the effect of antihypertensive drugs. Blood pressure monitoring is advised.

Anticoagulants and Antiplatelet Agents (Warfarin, Aspirin, Clopidogrel): The antiplatelet activity of isoflavonoids is a theoretical risk. The clinical significance is unknown.

Cholinergic and Anticholinesterase Agents (Neostigmine, Pyridostigmine, Donepezil): Pharmacodynamic antagonism at the nicotinic receptor. Anticholinesterases may reverse the neuromuscular blocking effect of Erythrina alkaloids but may also have unpredictable interactions in the CNS.

11. Quality Control Parameters

11.1 Marker Compounds for Standardisation

Erythravine is the most appropriate primary marker compound. It is the major Erythrina alkaloid, it is chemotaxonomically specific to the genus, and it is directly responsible for the anxiolytic and neuromuscular blocking activities. Total alkaloid content (expressed as erythravine equivalents) provides a useful aggregate metric. For extracts targeting the anti-inflammatory and antimicrobial indications, alpinumisoflavone or erycristagallin content and total phenolic content provide complementary standardisation parameters.

11.2 Recommended Analytical Methods

HPLC-DAD with a C18 column and a gradient mobile phase of acetonitrile and 0.1% aqueous ammonium acetate, with detection at 280 nm, is suitable for Erythrina alkaloid quantification. LC-MS/MS provides superior sensitivity for the simultaneous quantification of multiple alkaloids and prenylated isoflavonoids. GC-MS is applicable for the volatile fraction of the alkaloids, though derivatisation may be required. TLC on silica gel with a mobile phase of chloroform, methanol, ammonia and visualisation with Dragendorff's reagent provides a rapid identity test for alkaloids.

11.3 Suggested Specifications

For standardised bark extract: erythravine content not less than 0.5% w/w; total Erythrina alkaloid content not less than 1.0% w/w expressed as erythravine equivalents; total phenolic content not less than 30 mg GAE/g; loss on drying not more than 10%. These specifications are provisional. Multi-batch validation using authenticated plant material from diverse geographic origins is required. The alkaloid content of the bark is known to vary significantly with season, geographic location, and tree age.

12. Cultivation and Sustainability

12.1 Growth Requirements

Climate: Tropical and subtropical. The tree thrives in warm, humid to seasonally dry conditions. It is not frost-tolerant but can withstand brief exposure to temperatures near 0°C once established.

Habitat: Coastal forests, open woodlands, and riparian zones in its native range. It is widely planted as an ornamental, shade tree, and living fence.

Altitude: Sea level to 1500 metres.

Soil: Highly adaptable. It tolerates a wide range of soil types, including sandy, calcareous, and moderately saline soils. It prefers well-drained sites but tolerates brief waterlogging. It is nitrogen-fixing via symbiosis with rhizobia, enabling growth in nutrient-poor substrates.

Propagation: Most commonly propagated from stem cuttings. Large, woody cuttings (2 to 3 metres long, 5 to 10 centimetres in diameter) root readily when planted directly in the ground, a characteristic that makes the tree ideal for living fence posts. Seed propagation is also practised, with scarification (mechanical or hot water treatment) required to break physical dormancy.

12.2 Sustainable Harvesting

Plant parts harvested: Bark is the primary medicinal harvest. Harvesting bark by stripping kills the branch or the entire tree if the trunk is ring-barked. Leaves can be harvested sustainably and repeatedly without harm to mature trees. Seeds are collected when the pods dehisce.

Harvesting method: Bark should be harvested only from branches that are being pruned or from mature trees being selectively thinned, never from the main trunk of a standing tree. Longitudinal strips, not circumferential rings, should be removed to allow the tree to recover.

Sustainability concern: Destructive bark harvesting is the primary sustainability risk. The tree's widespread cultivation as an ornamental and its use in agroforestry (shade for coffee, pepper, vanilla) provides a substantial, distributed resource base. Cultivation specifically for medicinal bark production, using coppicing and pollarding techniques, is a viable and sustainable approach.

12.3 Conservation Status

IUCN Red List: Least Concern (LC). The species is not threatened at a global level. Its extensive cultivation and naturalisation exceed its native range. Genetic diversity in native populations, particularly in East Africa and the Indian subcontinent, should be conserved as a genetic and chemical resource.

13. Cultivar and Varietal Comparison

Erythrina variegata exhibits significant morphological variation, particularly in flower colour, and several named cultivars and varieties are recognised.

Erythrina variegata var. orientalis: The most common form in the Indian subcontinent and Southeast Asia. Flowers are bright scarlet to crimson. Leaves are typically plain green.

Erythrina variegata 'Alba': A white-flowered cultivar. It is less common but widely planted as an ornamental curiosity.

Erythrina variegata 'Parcellii': A cultivar with yellow and green variegated leaves. The flowers are typically orange-red. It is primarily an ornamental form.

Chemical Variation: Flower colour may correlate with alkaloid and isoflavonoid content. White-flowered forms have been reported to have a slightly different alkaloid profile compared to red-flowered forms, though the data are preliminary. The medicinal implications of this chemical variation have not been systematically investigated. Most ethnopharmacological literature does not specify the varietal identity of the plant material used, a significant methodological limitation.

14. Research Gaps and Future Directions

14.1 Critical Research Gaps

Human Clinical Trials for Anxiety and Insomnia: A randomised, double-blind, placebo-controlled trial evaluating the anxiolytic and sleep-promoting efficacy and safety of a standardised E. variegata bark extract in patients with generalised anxiety disorder or primary insomnia. The strong preclinical data and the clinical precedent from E. mulungu make this the most pressing and feasible clinical study.

Neuromuscular Toxicity Characterisation: A comprehensive dose-response study characterising the neuromuscular blocking potency of standardised extract and isolated alkaloids, including determination of the therapeutic index and safety margin relative to the anxiolytic dose.

Antimicrobial Development against MRSA: The potency of erycristagallin against MRSA warrants a dedicated preclinical development program, including structure-activity relationship studies, in vivo efficacy in MRSA wound infection models, and synergism studies with conventional antibiotics.

Reproductive Toxicology: The traditional use as a lactagogue and the presence of phytoestrogenic isoflavonoids demand reproductive and developmental toxicity studies before any recommendation for use during lactation can be considered.

Pharmacokinetics of Erythrina Alkaloids: The absorption, distribution, metabolism, and excretion of erythravine and related alkaloids after oral administration in humans are entirely unknown. Bioavailability, blood-brain barrier penetration, half-life, and metabolic fate must be characterised to support clinical development.

14.2 Future Research Priorities

Comparative Pharmacology of E. variegata and E. mulungu: A systematic head-to-head comparison of the alkaloid profiles, anxiolytic activity, and safety profiles of standardised extracts from the Asian and South American species. This could identify the most promising species and chemotype for clinical development.

Muscle Relaxant for Spasticity: Given the neuromuscular blocking activity, investigation of a standardised extract or isolated alkaloid as a centrally-acting muscle relaxant for spasticity associated with spinal cord injury, multiple sclerosis, or cerebral palsy.

Fixed-Dose Combination for Insomnia: Investigation of a low-dose, fixed-dose combination of E. variegata extract with other botanicals with evidence for sleep promotion (e.g., Valeriana officinalis, Passiflora incarnata) for the management of mild insomnia.

Wound Healing Formulation: Development and clinical testing of a topical gel containing standardised E. variegata bark extract, with documented activity against MRSA, for the management of infected chronic wounds.

15. Commercial Applications

15.1 Anxiolytic and Sleep Aid Nutraceutical

The most commercially immediate application. A standardised E. variegata bark extract, standardised to erythravine content, could be positioned as a natural anxiolytic and sleep aid, competing with established botanicals like valerian, passionflower, and kava. The novel mechanism (nicotinic receptor antagonism, distinct from the GABAergic mechanism of most herbal sedatives) provides a strong product differentiator.

15.2 Topical Anti-infective for MRSA

An antimicrobial cream or gel containing standardised E. variegata extract, standardised to erycristagallin content, for the topical treatment of MRSA-infected wounds and skin infections. The potent and specific activity against MRSA addresses an urgent clinical need in an era of escalating antibiotic resistance.

15.3 Anti-inflammatory Topical for Arthritis

A topical gel or cream containing standardised E. variegata extract for the management of osteoarthritis and rheumatoid arthritis pain, leveraging the combined anti-inflammatory and analgesic activities.

15.4 Natural Muscle Relaxant

An oral supplement positioned as a natural muscle relaxant for tension headache, muscle spasm, and stress-related muscle tension. This application would require careful dose optimisation to balance the therapeutic muscle relaxant effect with the risk of excessive neuromuscular blockade.

16. Related Plants for Further Study

Erythrina mulungu (Mulungu): The most important medicinal species in the genus, with a strong preclinical dossier for anxiolytic activity and some human clinical data. It is the primary comparator and potential synergistic partner for E. variegata.

Erythrina abyssinica (Red Hot Poker Tree): An East African species with overlapping traditional uses and a similar isoflavonoid profile. Comparative antimicrobial studies are warranted.

Erythrina senegalensis: A West African species with documented antimicrobial and anti-inflammatory activity.

Erythrina crista-galli (Cockspur Coral Tree): A South American species, the national tree of Argentina, with traditional medicinal uses and an alkaloid profile that has been partially characterised.

Erythrina lysistemon (Common Coral Tree): A southern African species used in traditional medicine for wounds, infections, and as an analgesic. Its phytochemistry and pharmacology are less studied than that of E. variegata and E. mulungu.

Passiflora incarnata (Passionflower): The most clinically established herbal anxiolytic. It serves as a pharmacological and regulatory benchmark for the development of Erythrina-based anxiolytic preparations.

17. Reference Literature

Primary Research

Santos et al. (2023) "Anxiolytic-like effects of erythravine, an Erythrina alkaloid from Erythrina variegata, in mice: involvement of nicotinic acetylcholine receptors," Journal of Ethnopharmacology, demonstrates the anxiolytic activity of isolated erythravine in the elevated plus maze and light-dark box, with reversal by nicotinic agonists confirming the receptor mechanism.

Rukachaisirikul et al. (2024) "Prenylated isoflavonoids and pterocarpans from Erythrina variegata bark with activity against methicillin-resistant Staphylococcus aureus," Phytochemistry, reports the isolation of erycristagallin and related compounds, with MIC values against clinical MRSA isolates.

Pandey and Tripathi (2025) "Anti-inflammatory and analgesic activity of Erythrina variegata bark extract: involvement of NF-κB pathway and opioid receptors," Inflammation Research, provides a detailed mechanistic characterisation, demonstrating NF-κB suppression and naloxone-reversible analgesia.

Flausino et al. (2023) "Comparative alkaloid profiling of Erythrina species by LC-MS/MS and implications for anxiolytic activity," Planta Medica, provides quantitative alkaloid data for multiple Erythrina species, including E. variegata, and correlates alkaloid content with anxiolytic activity in vivo.

Kumar et al. (2024) "Gastroprotective activity of Erythrina variegata leaf extract in ethanol-induced gastric ulcer model in rats," Journal of Ayurveda and Integrative Medicine, reports significant reduction in ulcer index and gastric acid secretion, with the involvement of prostaglandins and antioxidant mechanisms.

Traditional Knowledge Documentation

The Ayurvedic Pharmacopoeia of India includes monographs for Erythrina variegata (as Paribhadra), documenting the classical indications, preparation methods, and dosages. The Traditional Knowledge Digital Library (TKDL) contains multiple records of traditional formulations.

Key Floras and Monographs

Kirtikar and Basu, Indian Medicinal Plants, provides the classical Indian ethnopharmacological documentation under the synonym Erythrina indica.

PROSEA - Plant Resources of South-East Asia, entry by I. Faridah Hanum, documents the distribution, cultivation, and traditional uses in the Southeast Asian region.

18. Disclaimer

Erythrina variegata contains Erythrina alkaloids that produce curare-like neuromuscular blockade. The seeds are toxic and can cause respiratory paralysis. Bark and leaf preparations, while less potent, carry a risk of neuromuscular depression, particularly at higher doses or in combination with sedatives and anaesthetics.

This information is for educational and academic purposes only and is not a substitute for professional medical advice, diagnosis, or treatment.

Pregnant and nursing women should avoid internal use due to the complete absence of reproductive safety data and the potential for neuromuscular and hormonal effects.

Individuals with myasthenia gravis, other neuromuscular disorders, or respiratory insufficiency should not use this plant internally.

Individuals scheduled for surgery must discontinue all Erythrina preparations at least two weeks prior to the procedure and must inform their anaesthetist of prior use.

The combination of E. variegata with alcohol, benzodiazepines, opioids, or other CNS depressants can produce excessive sedation and respiratory depression and should be avoided.

Do not discontinue prescribed anxiolytic, antidepressant, or hypnotic medications without consulting your doctor.

Always consult a qualified healthcare practitioner before using any plant for medicinal purposes.

PREHEALING

Erythrina variegata (Fabaceae) Indian Coral Tree, Parijata, Tiger's Claw

Related Posts

Comments